Aminologics Co.Ltd (074430) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Aminologics Co.Ltd (074430) has a cash flow conversion efficiency ratio of -0.074x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-4.16 Billion ≈ $-2.82 Million USD) by net assets (₩56.08 Billion ≈ $38.00 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Aminologics Co.Ltd - Cash Flow Conversion Efficiency Trend (2008–2024)
This chart illustrates how Aminologics Co.Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read 074430 total liabilities for a breakdown of total debt and financial obligations.
Aminologics Co.Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Aminologics Co.Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
OSE Pharma SA
PA:OSE
|
-0.355x |
|
Full House Resorts Inc
NASDAQ:FLL
|
-0.001x |
|
M&G Plc
LSE:MNG
|
-0.029x |
|
Anfield Energy Inc.
NASDAQ:AEC
|
-0.070x |
|
Embellence Group AB
ST:EMBELL
|
0.059x |
|
Reworld Media
PA:ALREW
|
0.011x |
|
Brand X Co. Ltd.
KQ:337930
|
-0.022x |
|
Somnomed Ltd
AU:SOM
|
0.083x |
Annual Cash Flow Conversion Efficiency for Aminologics Co.Ltd (2008–2024)
The table below shows the annual cash flow conversion efficiency of Aminologics Co.Ltd from 2008 to 2024. For the full company profile with market capitalisation and key ratios, see 074430 market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩51.70 Billion ≈ $35.03 Million |
₩7.47 Billion ≈ $5.06 Million |
0.144x | +3702.19% |
| 2023-12-31 | ₩54.41 Billion ≈ $36.87 Million |
₩-218.15 Million ≈ $-147.84K |
-0.004x | -103.94% |
| 2022-12-31 | ₩51.40 Billion ≈ $34.84 Million |
₩5.23 Billion ≈ $3.54 Million |
0.102x | +545.46% |
| 2021-12-31 | ₩59.39 Billion ≈ $40.25 Million |
₩935.52 Million ≈ $633.99K |
0.016x | -52.29% |
| 2020-12-31 | ₩53.56 Billion ≈ $36.30 Million |
₩1.77 Billion ≈ $1.20 Million |
0.033x | -52.50% |
| 2019-12-31 | ₩51.85 Billion ≈ $35.14 Million |
₩3.60 Billion ≈ $2.44 Million |
0.070x | -18.90% |
| 2018-12-31 | ₩53.19 Billion ≈ $36.04 Million |
₩4.56 Billion ≈ $3.09 Million |
0.086x | +28.94% |
| 2017-12-31 | ₩45.14 Billion ≈ $30.59 Million |
₩3.00 Billion ≈ $2.03 Million |
0.066x | -28.45% |
| 2016-12-31 | ₩44.55 Billion ≈ $30.19 Million |
₩4.14 Billion ≈ $2.80 Million |
0.093x | +132.53% |
| 2015-12-31 | ₩48.28 Billion ≈ $32.72 Million |
₩1.93 Billion ≈ $1.31 Million |
0.040x | +161.59% |
| 2014-12-31 | ₩31.85 Billion ≈ $21.58 Million |
₩-2.07 Billion ≈ $-1.40 Million |
-0.065x | -127.90% |
| 2008-12-31 | ₩52.44 Billion ≈ $35.54 Million |
₩12.19 Billion ≈ $8.26 Million |
0.233x | -- |
About Aminologics Co.Ltd
Aminologics Co.,Ltd., a specialty amino acid provider, develops a range of amino-acid-based raw materials for pharmaceutical and fine chemical industries in South Korea. Its products include D-phenylalanine, D-alanine, D-cysteine, D-serine, D-allo-isoleucine, D-allo-threonine, S-beta-phenylalanine, 3-(2-napthyl)-D-alanine, 4-chloro-D-phenylalanine, 3-(2-napthyl)-L-alanine, R-beta-phenylalanine, D… Read more